iifl-logo

Indoco Remedies Ltd Board Meeting

255.16
(4.56%)
Apr 3, 2025|02:29:58 PM

Indoco Remedies CORPORATE ACTIONS

03/04/2024calendar-icon
03/04/2025calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting25 Mar 202525 Mar 2025
The Board of Directors of the Company at their meeting held on 25-03-2025 has interalia considered and approved the following: Reappointment of M/s. Joshi Apte & Associates, Cost Accountants, as the Cost Auditors of the Company for the financial year 2025-2026
Board Meeting21 Jan 202513 Jan 2025
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2025 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended 31-12-2024 Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 21st January, 2025 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2024 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2024 (As per BSE Announcement Dated on 21/01/2025)
Board Meeting24 Oct 202414 Oct 2024
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2024 inter alia to consider and approve The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended 30-09-2024 Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 24th October, 2024 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September, 2024 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. Read less.. Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September, 2024 (As Per BSE Announcement Dated on 24.10.2024)
Board Meeting23 Jul 202410 Jul 2024
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2024 inter alia to consider and approve the Unaudited Standalone & Consolidated Financial Results of the Company for the quarter ended 30-06-2024 Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 23rd July, 2024 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2024 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. (As per BSE Announcement Dated on 23/07/2024)
Board Meeting16 May 20248 May 2024
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2024 inter alia to consider and approve 1. The Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended 31st March 2024. 2. To recommend a final dividend if any for the financial year ending 31st March 2024. Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 (Listing Regulations), we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 16th May, 2024 has inter-alia considered and approved the following. 1. Audited Financial Results (Consolidated and Standalone) for the quarter and year ended 31st March, 2024 and Auditors Reports with unmodified opinions on the aforesaid Audited Financial Results. 2. Subject to the approval of the Members at the ensuing 77th Annual General Meeting, recommended a Dividend of Rs. 1.50 per equity share on face value of Rs. 2/- for the financial year 2023-2024 Approval of Standalone and Consolidated Financial Results for the Quarter and Year ended 31st March, 2024 (As per BSE Announcement Dated on 16/05/2024)

Indoco Remedies: Related News

USFDA Inspects Indoco’s AnaCipher Unit, Issues Form 483
11 Mar 2025|01:48 PM

Indoco Remedies stated that it will respond to the Form 483 observations within the prescribed timeline.

Read More
Top Stocks for Today - 11th March 2025
11 Mar 2025|07:11 AM

Here are some of the stocks that may see significant price movement today: IndusInd Bank, Hindustan Zinc, Thermax, etc.

Read More
Indoco Partners with Clarity Pharma to Launch 20 Affordable Drugs in UK
4 Dec 2024|01:37 PM

Indoco Remedies will also continue providing products to its existing B2B customers under existing deals.

Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.